

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

| Name | Role in Activity | Ineligible Company | Nature of Relevant Financial Relationship |
|---|-------------------------------|---|---|
| Mark Agulnik, MD (Keck) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Aref Al-Kali, MD (Mayo Clinic) | Speaker | <ul style="list-style-type: none"> Novartis ALX Oncology, Aprea, Astex, H3B/Hemavant, Novartis | <ul style="list-style-type: none"> Consultant Research Funding |
| Tanya Barauskas Dorff, MD (City of Hope) | Speaker | <ul style="list-style-type: none"> AstraZeneca, Bayer, Janssen, Sanofi | <ul style="list-style-type: none"> Advisory Board |
| Aditya Bardia, MD (UCLA) | Speaker | <ul style="list-style-type: none"> Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly, Alyssum Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly | <ul style="list-style-type: none"> Consultant Research Funding |
| Brian Bednarski, MD (MD Anderson) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Munveer Bhangoo, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> Exelixis, BMS Foundation Medicine | <ul style="list-style-type: none"> Speaker Consultant |
| Kathryn Bollin, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Thomas Buchholz, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> Nucleix, Emyprean | <ul style="list-style-type: none"> Stock Options |
| Ramez Eskander, MD (UCSD) | Speaker | <ul style="list-style-type: none"> Clovis Oncology, GSK, Merck, AstraZeneca AstraZeneca, Clovis, Eisai, GSK, ImmunoGen, Mersana, Myriad, Novocure, Onconova, Elevar Therapeutics, Daiichi Sankyo AstraZeneca, GSK, ImmunoGen, Medscape, CURIO, Great Debates and Updates | <ul style="list-style-type: none"> Research Funding Consultant Honoraria |
| Morie Gertz, MD (Mayo Clinic) | Speaker | <ul style="list-style-type: none"> Ionis/Akcea, Alnylym, Prothena, Sanofi, Janssen, AbbVie, Johnson & Johnson, AstraZeneca, Medscape, Dava Oncology, Alexion | <ul style="list-style-type: none"> Speaking Honorarium |
| Jason Gotlib, MD (Stanford) | Speaker | <ul style="list-style-type: none"> Blueprint Medicines, Cogent Biosciences, Telios Blueprint Medicines, Cogent Biosciences, Telios | <ul style="list-style-type: none"> Research Support Consultant, Advisory Board |

| Name | Role in Activity | Ineligible Company | Nature of Relevant Financial Relationship |
|--|-------------------------------|--|--|
| David Hermel, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Damon Houghton, MD (Mayo Clinic) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Laura Huppert, MD (UCSF) | Speaker | <ul style="list-style-type: none"> AstraZeneca, Pfizer | <ul style="list-style-type: none"> Consultant |
| Eugene Koay, MD (MD Anderson) | Speaker | <ul style="list-style-type: none"> National Institutes of Health, Elekta, Philips Healthcare, GE, MD Anderson Cancer Center | <ul style="list-style-type: none"> Grant Funding |
| Alice Ma, MD (UNC) | Speaker | <ul style="list-style-type: none"> Pfizer | <ul style="list-style-type: none"> Advisory Board |
| James Mason, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> AbbVie | <ul style="list-style-type: none"> Consultant |
| Stephan Moll, MD (UNC) | Speaker | <ul style="list-style-type: none"> Stago Diagnostics | <ul style="list-style-type: none"> Consultant |
| Seema Nagpal, MD (Stanford) | Speaker | <ul style="list-style-type: none"> Novocure, Mirati, Servier, Kiyatec, Telix, Midatech | <ul style="list-style-type: none"> Consultant |
| Michael Overman, MD (MD Anderson) | Speaker | <ul style="list-style-type: none"> Array BioPharma, Bristol Myers Squibb, Gritstone Oncology, Janssen, MedImmune, Novartis, Pfizer, Promega, Roche/Genentech, Spectrum Pharmaceuticals Bristol Myers Squibb, MedImmune, Merck, Roche | <ul style="list-style-type: none"> Consultant, Advisory Board Research Funding |
| Menaka Pai, MD (McMaster) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Sumanta Kumar Pal, MD (City of Hope) | Speaker | <ul style="list-style-type: none"> Roche, Genentech, Exelixis, Eisai, Pfizer Roche | <ul style="list-style-type: none"> Research Funding Consultant |
| Kamya Sankar, MD (Cedars-Sinai) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Alan Saven, MD (Scripps) | Planning Committee, Moderator | <ul style="list-style-type: none"> Beigene, Janssen, Eli Lilly, Incyte | <ul style="list-style-type: none"> Speaker's Bureau |
| Stephen Schuster, MD (Penn Med) | Speaker | <ul style="list-style-type: none"> AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Incyte, Janssen, Legend Biotech, Loxo Oncology, Novartis, Regeneron Genentech, Merck | <ul style="list-style-type: none"> Consultant Grant Funding |
| Darren Sigal, MD (Scripps) | Course Director | <ul style="list-style-type: none"> Ipsen Seagen Agenus, BMS | <ul style="list-style-type: none"> Speaker's Bureau, Consultant Speaker's Bureau Advisory Board |
| Wendy Stock, MD (University of Chicago) | Speaker | <ul style="list-style-type: none"> None | <ul style="list-style-type: none"> N/A |
| Jonathan Strosberg, MD (Moffitt) | Speaker | <ul style="list-style-type: none"> Novartis, Radiomedix, RayzeBio Boehringer-Ingelheim | <ul style="list-style-type: none"> Grant/Research Funding Consultant, Advisory Board |
| Ted Warkentin, MD (McMaster) | Speaker | <ul style="list-style-type: none"> Werfen | <ul style="list-style-type: none"> Consultant, Research Support |

| Name | Role in Activity | Ineligible Company | Nature of Relevant Financial Relationship |
|-----------------------------------|--|--|--|
| Eric Yang, MD (UCLA) | Speaker | <ul style="list-style-type: none"> • Amgen, Boehringer-Ingelheim, BMS, CSL Behring, Eli Lilly • Edwards Lifesciences, National Comprehensive Cancer Center, Xencor, Zoll Medical | <ul style="list-style-type: none"> • Research Funding • Consultant |
| CME Committee | CE approval, all final decision-making on activities | <ul style="list-style-type: none"> • None | <ul style="list-style-type: none"> • N/A |
| Scripps Conference Services & CME | Plan, manage, implement, and reconcile CE activities | <ul style="list-style-type: none"> • None | <ul style="list-style-type: none"> • N/A |

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.